Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Chikako Matsumura"'
Autor:
Chikako Matsumura, Nanako Koyama, Kaho Okuno, Nobuhiko Nakamura, Morito Sako, Hideo Kurosawa, Takehisa Nomura, Yuki Eguchi, Kazuki Ohba, Yoshitaka Yano
Publikováno v:
Palliative Medicine Reports, Vol 4, Iss 1, Pp 202-207 (2023)
Background: Prognostics for patients with cancer is especially important for the supportive care of those who are terminally ill. We previously found that symptom scores as patient-reported outcomes (PROs)?such as dyspnea and fatigue scores?some bioc
Externí odkaz:
https://doaj.org/article/77d096002d40413bbb0f348d0eef91da
Autor:
Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Publikováno v:
Cancer Control, Vol 29 (2022)
Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the associat
Externí odkaz:
https://doaj.org/article/eddb51a987b846bf81938b3f26131ad8
Autor:
Nanako Koyama, Chikako Matsumura, Yoshihiro Shitashimizu, Morito Sako, Hideo Kurosawa, Takehisa Nomura, Yuki Eguchi, Kazuki Ohba, Yoshitaka Yano
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The clinical use of patient-reported outcomes as compared to inflammatory biomarkers for predicting cancer survival remains a challenge in palliative care settings. We evaluated the role of the European Organization for Research a
Externí odkaz:
https://doaj.org/article/2c1c9ba5e14f4bb3a8f12965b5a0fb93
Autor:
Hiroki Hata MS, Tadashi Mio PhD, Daisuke Yamashita BS, Chikako Matsumura PhD, Yugo Chisaki PhD, Hideyuki Motohashi PhD, Yoshitaka Yano PhD
Publikováno v:
Cancer Control, Vol 27 (2020)
Background and Objectives: Immune-checitors have been established as a novel standard treatment for non-small cell lung cancer (NSCLC). The aim of this study was to identify factors associated with efficacy and nivolumab-related interstitial pneumoni
Externí odkaz:
https://doaj.org/article/e6ba1825eefa4d269e50dda50bb55568
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:323-332
Immune checkpoint inhibitors (ICIs) are associated with peculiar adverse events related to the mechanism of action. Less than 1% of patients treated with ICIs develop autoimmune encephalitis. The aim of this study was to compare the frequency of ence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e890d99f4dc8968520f0b3637da4043
https://doi.org/10.1007/s43441-021-00365-x
https://doi.org/10.1007/s43441-021-00365-x
Autor:
null Hiroki Hata, null Chikako Matsumura, null Yugo Chisaki, null Kae Nishioka, null Misaki Tokuda, null Kazuyo Miyagi, null Tomoki Suizu, null Yoshitaka Yano
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::985e82c8ab28532925b1feb218174a3f
https://doi.org/10.1177/10732748221130576/v2/response1
https://doi.org/10.1177/10732748221130576/v2/response1
Autor:
Yoshitaka Yano, Yuki Eguchi, Yuuna Tahara, Kazuki Ohba, Takehisa Nomura, Nanako Koyama, Hideo Kurosawa, Morito Sako, Chikako Matsumura
Publikováno v:
Supportive Care in Cancer
Purpose The aims of the present study were to investigate the symptom clusters in terminally ill patients with cancer using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care (EORTC QL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250980e72f24af46216df44133f52170
https://doi.org/10.1007/s00520-021-06380-w
https://doi.org/10.1007/s00520-021-06380-w
Publikováno v:
Clinical Drug Investigation. 41:381-389
Atezolizumab is an anti-programmed death ligand 1 (PD-L1) antibody that shows good safety and efficacy for patients with PD-L1-positive triple-negative breast cancer (TNBC). The cost of atezolizumab therapy is expensive, and its economic burden is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd9cbc677b6acdcb3f35960c686ee423
https://doi.org/10.1007/s40261-021-01017-6
https://doi.org/10.1007/s40261-021-01017-6
Autor:
Masami Yamada, Rie Ueno, Yumi Jimaru, Kazushige Takahashi, Chikako Matsumura, Sari Torii, Yoshitaka Yano
Publikováno v:
Palliative Care Research. 15:213-220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab4dd73cb51640b285b6c45b6986ef59
https://doi.org/10.2512/jspm.15.213
https://doi.org/10.2512/jspm.15.213
Autor:
Daisuke Yamashita, Hiroki Hata, Hideyuki Motohashi, Yoshitaka Yano, Tadashi Mio, Chikako Matsumura, Yugo Chisaki
Publikováno v:
Cancer Control : Journal of the Moffitt Cancer Center
Cancer Control, Vol 27 (2020)
Cancer Control, Vol 27 (2020)
Background and Objectives: Immune-checitors have been established as a novel standard treatment for non-small cell lung cancer (NSCLC). The aim of this study was to identify factors associated with efficacy and nivolumab-related interstitial pneumoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da08411e8647614e2a05be7938c8c83b
http://europepmc.org/articles/PMC8480353
http://europepmc.org/articles/PMC8480353